FDA Approves PROLIA — Amgen, Inc

Amgen’s (NASDAQ: AMGN) approval of the subcutaneous DENOSUMAB formulation shows the biotech giant intends to leverage the format’s improved dosing convenience to untether the brand from the traditional reimbursement constraints associated with intravenous administration. This strategic pivot positions the blockbuster osteoporosis therapy for potential expansion into new patient pools and reduces the total cost of care, creating acute pricing pressure on current injectable competitors.